Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Novel antibody helps patients with advanced gastric cancer live longer

2016 ASCO Annual Meeting

Published: 5 Jun 2016

Views: 1983

Rating:

Save

Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany

Prof Al-Batran presents at ASCO 2016, findings from a European phase II study which showed that the novel, first-in- class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 months vs. 8.4 months) for patients with advanced gastric cancer.

Watch the video interview and read the news story for more.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

High-dose ifosfamide standard of care for recurrent and primary refractory...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

More from ecancer